AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26161000 — intervention group
Group type: COMPARATOR
Intervention: Group C (crossword puzzle training)
Number of subjects: 37
Study 24660271 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing mouthrinse (EO)
Number of subjects: 185
Study 24660271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride mouthrinse (CPC)
Number of subjects: 185
Study 24660271 — intervention group
Group type: COMPARATOR
Intervention: Negative control (5% hydroalcohol rinse)
Number of subjects: 185
Study 21205944 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF(low)
Number of subjects: 1707
Study 21205944 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF(mid)
Number of subjects: 1707
Study 21205944 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF(high)
Number of subjects: 1707
Study 18507536 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ostial pulmonary vein isolation attempted regardless of anatomical relationship to the esophagus (group A)
Number of subjects: 43
Study 16620257 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy group prenatal care
Number of subjects: 0
Study 12821430 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 4953
Study 12821430 — intervention group
Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 4953
Study 10682943 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise testing for total work capacity (TWC, kg.m)
Number of subjects: 265
Study 10682943 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise testing for peak oxygen consumption (VO2peak, mL/kg/min)
Number of subjects: 265
Study 8656171 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg four times daily for 10 days
Number of subjects: 140
Study 8656171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1672176 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204.219 (40 mg single oral dose)
Number of subjects: 10
Study 1672176 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study 6307464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 5 mg/kg twice daily during granulocytopenia
Number of subjects: 59
Study 6307464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 6307464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 59
Study 31977370 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg chlorzoxazone 3 times daily for the first 7 days postoperatively
Number of subjects: 393
Study 31977370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 31383725 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin identified in abstracts of RCTs
Number of subjects: 116
Study 31383725 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin in titles
Number of subjects: 116
Study 31383725 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin in abstract results sections
Number of subjects: 116
Study 31383725 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin in abstract conclusion sections
Number of subjects: 116
Study 31383725 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous spin in results and conclusions sections
Number of subjects: 116
Study 31383725 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry funding and spin relationship
Number of subjects: 116
Study 28552271 — intervention group
Group type: COMPARATOR
Intervention: Standard Valsalva maneuver (VM)
Number of subjects: 56
Study 28552271 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Valsalva maneuver (VM)
Number of subjects: 56
Study 26434934 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 151 (50, 100, or 200mg twice daily)
Number of subjects: 236
Study 26434934 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 151 (100, 200, or 400mg once daily)
Number of subjects: 236
Study 26434934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 24225595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose whey protein isolate (0.8 g·kg1·d1; W1)
Number of subjects: 9
Study 24225595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose whey protein isolate (1.6 g·kg1·d1; W2)
Number of subjects: 9
Study 24225595 — intervention group
Group type: COMPARATOR
Intervention: Control condition (typical mixed diet with 10% protein)
Number of subjects: 9
Study 24225595 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (calorically matched with carbohydrate)
Number of subjects: 9
Study 22423128 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (exact dosage and duration not specified)
Number of subjects: 1
Study 19369380 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein (eHF-C)
Number of subjects: 1840
Study 19369380 — intervention group
Group type: COMPARATOR
Intervention: Partially hydrolyzed whey (pHF-W)
Number of subjects: 1840
Study 19369380 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey (eHF-W)
Number of subjects: 1840
Study 19369380 — intervention group
Group type: COMPARATOR
Intervention: Cow-milk formula (CMF)
Number of subjects: 1840
Study 19369380 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 1840
Study 17186304 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 20 subjects
Number of subjects: 30
Study 17186304 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - 10 subjects
Number of subjects: 30
Study 15058116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 25 micrograms
Number of subjects: 60
Study 15058116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 60
Study 15058116 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram.kg‐1
Number of subjects: 60
Study 15058116 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine with 5 ml saline (Control Group L)
Number of subjects: 60
Study 11407430 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirectly related words (e.g., sofa) used as primes for low-frequency inconsistent words in naming tasks.
Number of subjects: 0
Study 11407430 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirectly related words (e.g., sofa) used as primes for high-frequency inconsistent words in a speeded naming task.
Number of subjects: 0
Study 11407430 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent words used as targets in naming tasks.
Number of subjects: 0
Study 9404209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuson 128
Number of subjects: 63
Study 9404209 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Quantum
Number of subjects: 63
Study 9404209 — intervention group
Group type: COMPARATOR
Intervention: Acuson 128 and Siemens Quantum
Number of subjects: 63
Study 9404209 — intervention group
Group type: COMPARATOR
Intervention: In vitro comparisons
Number of subjects: 63
Study 8219679 — intervention group
Group type: EXPERIMENTAL
Intervention: Xue Zhi Ling
Number of subjects: 92
Study 8219679 — intervention group
Group type: COMPARATOR
Intervention: Control group (panagin)
Number of subjects: 92
Study 3306500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered cefuroxime and metronidazole (three-dose perioperative course)
Number of subjects: 0
Study 3306500 — intervention group
Group type: COMPARATOR
Intervention: Suction drainage of the vaginal vault
Number of subjects: 0
Study 3306500 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 29371115 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM at 33 °C
Number of subjects: 939
Study 29371115 — intervention group
Group type: COMPARATOR
Intervention: TTM at 36 °C
Number of subjects: 939
Study 29371115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation administered in treatment groups
Number of subjects: 939
Study 27180890 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily
Number of subjects: 30
Study 23931131 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaya test meal
Number of subjects: 16
Study 23931131 — intervention group
Group type: COMPARATOR
Intervention: Carrot test meal
Number of subjects: 16
Study 23931131 — intervention group
Group type: COMPARATOR
Intervention: Tomato test meal
Number of subjects: 16
Study 23394782 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimulation with highly purified human menopausal gonadotropin (hphMG) or recombinant FSH in a GnRH antagonist cycle.
Number of subjects: 749
Study 20145572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise (12 weeks, 1 hour, 2 times per week)
Number of subjects: 50
Study 20145572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pilates exercise)
Number of subjects: 50
Study 18001794 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone catheter
Number of subjects: 85
Study 18001794 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel coated latex catheter
Number of subjects: 85
Study 16432672 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO(2)-sensitive adaptive backup support
Number of subjects: 11
Study 16432672 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (control)
Number of subjects: 11
Study 12638172 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking habit
Number of subjects: 9629
Study 10761538 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized ginseng extract
Number of subjects: 384
Study 10761538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 7628032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 micrograms.kg-1)
Number of subjects: 38
Study 7628032 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 38
Study 1974498 — intervention group
Group type: EXPERIMENTAL
Intervention: S(−)‐CARV after i.v. administration
Number of subjects: 10
Study 1974498 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐CARV after i.v. administration
Number of subjects: 10
Study 1974498 — intervention group
Group type: EXPERIMENTAL
Intervention: S(−)‐CARV after p.o. administration
Number of subjects: 10
Study 1974498 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐CARV after p.o. administration
Number of subjects: 10
Study 1974498 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enantiomers
Number of subjects: 10
Study 1974498 — intervention group
Group type: EXPERIMENTAL
Intervention: S(−)‐CARV and R(+)‐CARV
Number of subjects: 10
Study 7220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) associated with hits
Number of subjects: 0
Study 7220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) associated with false affirmatives
Number of subjects: 0
Study 7220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) associated with misses and correct rejections
Number of subjects: 0
Study 7220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak latencies
Number of subjects: 0
Study 31174586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) followed by rituximab
Number of subjects: 80
Study 31174586 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions of 1% albumin followed by 0.9% sodium chloride
Number of subjects: 80
Study 29097298 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivofit2®; behavioural feedback and goal setting session; and, five telephone‐delivered health coaching sessions
Number of subjects: 0
Study 29097298 — intervention group
Group type: COMPARATOR
Intervention: Garmin Vivofit2® only
Number of subjects: 0
Study 27085996 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA + DHA supplementation (600 mg EPA and 260 mg DHA per day)
Number of subjects: 24
Study 27085996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 24775812 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (10 doses of 500 mg every 12 hours during 5 days)
Number of subjects: 671
Study 24775812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin-trometamol (2 doses of 3g every 48 hours)
Number of subjects: 671
Study 22683945 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma
Number of subjects: 0
Study 22683945 — intervention group
Group type: COMPARATOR
Intervention: Neutral Match
Number of subjects: 0
Study 20970233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention leaflet
Number of subjects: 104
Study 20970233 — intervention group
Group type: COMPARATOR
Intervention: Foundation leaflet (control)
Number of subjects: 104
Study 20970233 — intervention group
Group type: COMPARATOR
Intervention: Local food leaflet (control)
Number of subjects: 104
Study 18363884 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in infants (n=20) for 1 year
Number of subjects: 91
Study 18363884 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in children > 3 years (n=27) for 2 years
Number of subjects: 91
Study 18363884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) in infants (n=22) for 1 year
Number of subjects: 91
Study 18363884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) in children > 3 years (n=22) for 2 years
Number of subjects: 91
Study 18363884 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in infants and children
Number of subjects: 91
Study 18363884 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treatment (1 mg/m²/day) in children
Number of subjects: 91
Study 15957834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferulate (SF) treatment for 4 weeks
Number of subjects: 102
Study 15957834 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 102
Study 12060619 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA RT-PCR
Number of subjects: 129
Study 12060619 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA RT-PCR
Number of subjects: 129
Study 12060619 — intervention group
Group type: EXPERIMENTAL
Intervention: PSCA RT-PCR
Number of subjects: 129
Study 12060619 — intervention group
Group type: EXPERIMENTAL
Intervention: PSCA PCR
Number of subjects: 129
Study 10548762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellasene
Number of subjects: 11
Study 10548762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Colonease)
Number of subjects: 11
Study 7703389 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin (2.5 ng/kg per minute for 90 min)
Number of subjects: 0
Study 7703389 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (5 mg/kg per minute for 90 min)
Number of subjects: 0
Study 7703389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of endothelin and L-arginine
Number of subjects: 0
Study 2283626 — intervention group
Group type: EXPERIMENTAL
Intervention: CT pelvimetry
Number of subjects: 50
Study 2283626 — intervention group
Group type: COMPARATOR
Intervention: Classical pelvimetry
Number of subjects: 50
Study 373560 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration sets changed every 24 hours
Number of subjects: 300
Study 373560 — intervention group
Group type: COMPARATOR
Intervention: Administration sets changed every 48 hours
Number of subjects: 300
Study 7039276 — intervention group
Group type: EXPERIMENTAL
Intervention: lopamidol 61% as the contrast medium
Number of subjects: 100
Study 7039276 — intervention group
Group type: COMPARATOR
Intervention: Conray
Number of subjects: 100
Study 30843481 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 49
Study 30037647 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis once daily for 12 months
Number of subjects: 404
Study 30037647 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 404
Study 30037647 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 404
Study 26957117 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVent®‐ASV
Number of subjects: 80
Study 26957117 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 80
Study 24599461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic forced use of the nondominant hand (left hand)
Number of subjects: 8
Study 22503174 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 42
Study 22503174 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 42
Study 22503174 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 42
Study 20178563 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (AF group)
Number of subjects: 69
Study 20178563 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (non-AF group)
Number of subjects: 69
Study 17503876 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training and long‐acting bronchodilatators
Number of subjects: 0
Study 17503876 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training and technical modalities (inspiratory pressure support and inspiratory muscle training)
Number of subjects: 0
Study 17503876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 0
Study 17503876 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 17503876 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromuscular electrical stimulation
Number of subjects: 0
Study 17503876 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and supplements (oxygen, oral creatine, anabolic steroids and polyunsaturated fatty acids)
Number of subjects: 0
Study 16037110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 mg every 3 h for a maximum of five doses
Number of subjects: 120
Study 16037110 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol 400 mg every 3 h for a maximum of five doses
Number of subjects: 120
Study 16037110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 120
Study 16037110 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 120
Study 12386040 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and brief intervention for excessive alcohol use
Number of subjects: 24
Study 10431992 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited anterior plication (LAP)
Number of subjects: 0
Study 10431992 — intervention group
Group type: COMPARATOR
Intervention: Superficial vein surgery (ligation and section of the major incompetent superficial veins)
Number of subjects: 0
Study 7748753 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 2 weeks
Number of subjects: 190
Study 7748753 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg/day for 4 weeks
Number of subjects: 190
Study 2407757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% octenidine mouthrinse
Number of subjects: 451
Study 2407757 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse (placebo)
Number of subjects: 451
Study 2407757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 451
Study 444785 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic speech
Number of subjects: 20
Study 444785 — intervention group
Group type: COMPARATOR
Intervention: Normal speech
Number of subjects: 20
Study 30049402 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 738
Study 30049402 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in organized sports
Number of subjects: 738
Study 30049402 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental leisure-time physical activity
Number of subjects: 738
Study 30049402 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental traffic safety perceptions
Number of subjects: 738
Study 28031378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-emotion graphic warnings
Number of subjects: 1205
Study 28031378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-emotion graphic warnings
Number of subjects: 1205
Study 28031378 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 1205
Study 25479804 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected HPV testing
Number of subjects: 5109
Study 25479804 — intervention group
Group type: COMPARATOR
Intervention: Clinician-collected HPV testing
Number of subjects: 5109
Study 24427672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 mcg/day plus oral Levocetirizine 5 mg/day (n: 21)
Number of subjects: 56
Study 24427672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 mcg/day plus oral Montelukast 10 mg/day (n: 21)
Number of subjects: 56
Study 24427672 — intervention group
Group type: COMPARATOR
Intervention: Topical Mometasone furoate 200 mcg/day (n: 14)
Number of subjects: 56
Study 21088253 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir treatment (3-day duration)
Number of subjects: 16
Study 18440147 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% menthol solution
Number of subjects: 0
Study 18440147 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% cinnamaldehyde solution
Number of subjects: 0
Study 18440147 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study 16848645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XL 300 to 450 mg/day
Number of subjects: 274
Study 16848645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 14572572 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone therapy
Number of subjects: 63
Study 14572572 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine (4 g o.d.)
Number of subjects: 63
Study 14572572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10846036 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation at 4 g/day
Number of subjects: 12
Study 10846036 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation + 60 min of exercise
Number of subjects: 12